Yervoy — Total Revenues
Bristol-Myers Squibb Yervoy — Total Revenues increased by 1.5% to $739.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 15.1%, from $642.00M to $739.00M. Over 3 years (FY 2021 to FY 2024), Yervoy — Total Revenues shows an upward trend with a 7.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration and clinical demand for the therapy, while a decrease may signal increased competition from biosimilars or newer therapeutic alternatives.
Detailed definition
This metric represents the total global net sales generated by the Yervoy product line, a monoclonal antibody used in im...
Peer comparison
Comparable to revenue metrics for specific blockbuster oncology drugs or flagship therapeutic assets at other large-cap pharmaceutical companies.
bmy_segment_yervoy_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $510.00M | $515.00M | $545.00M | $515.00M | $525.00M | $523.00M | $568.00M | $508.00M | $585.00M | $579.00M | $566.00M | $583.00M | $630.00M | $642.00M | $675.00M | $624.00M | $728.00M | $739.00M |
| QoQ Change | — | +1.0% | +5.8% | -5.5% | +1.9% | -0.4% | +8.6% | -10.6% | +15.2% | -1.0% | -2.2% | +3.0% | +8.1% | +1.9% | +5.1% | -7.6% | +16.7% | +1.5% |
| YoY Change | — | — | — | — | +2.9% | +1.6% | +4.2% | -1.4% | +11.4% | +10.7% | -0.4% | +14.8% | +7.7% | +10.9% | +19.3% | +7.0% | +15.6% | +15.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's yervoy — total revenues?
- Bristol-Myers Squibb (BMY) reported yervoy — total revenues of $739.00M in Q3 2025.
- How has Bristol-Myers Squibb's yervoy — total revenues changed year-over-year?
- Bristol-Myers Squibb's yervoy — total revenues increased by 15.1% year-over-year, from $642.00M to $739.00M.
- What is the long-term trend for Bristol-Myers Squibb's yervoy — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's yervoy — total revenues has grown at a 7.7% compound annual growth rate (CAGR), from $2.03B to $2.53B.
- What does yervoy — total revenues mean?
- The total revenue generated from the sales of the Yervoy drug product.